Literature DB >> 36259133

Predictors of carbapenem-resistant Enterobacteriaceae (CRE) strains in patients with COVID-19 in the ICU ward: a retrospective case-control study.

Nicoleta-Dorina Vlad1,2, Roxana Carmen Cernat1,3, Sorina Carp1, Romelia Mitan1, Andrei Dumitru2, Codruța Nemet4, Septimiu Voidăzan5, Sorin Rugină2,6,7, Irina-Magdalena Dumitru1,3,2,6.   

Abstract

OBJECTIVE: To identify carbapenem-resistant Enterobacteriaceae (CRE) in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) and to determine whether they had different risk factors for the acquisition of CRE than patients without COVID-19.
METHODS: This retrospective single-centre, case-control study enrolled patients with and without COVID-19. The demographic, clinical, infection, colonization and mortality data were compared between the two groups.
RESULTS: A total of 38 patients with COVID-19 and 26 patients without COVID-19 were enrolled. The majority of isolates detected in COVID-19 patients were Klebsiella spp. Leukopenia at admission (odds ratio [OR] 4.70; 95% confidence interval [CI] 1.37, 16.10), invasive mechanical ventilation (OR 5.74; 95% CI 1.07, 30.63), carbapenem treatment (OR 5.09; 95% CI 1.21, 21.27) and corticosteroid treatment (OR 7.06; 95% CI 1.53, 32.39) were independent risk factors for CRE acquisition in COVID-19 patients. Intensive care unit (ICU) mortality was significantly higher in COVID-19 patients compared with patients without COVID-19 (OR 20.62; 95% CI 5.50, 77.23). Length of ICU stay increased the risk of death in patients with COVID-19 (subdistribution hazard ratio 3.81; 95% CI 1.33, 10.92).
CONCLUSION: CRE strains were more common in patients with COVID-19 and they had different risks for CRE compared with patients without COVID-19.

Entities:  

Keywords:  COVID-19; Carbapenem-resistant Enterobacteriaceae; risk factors

Mesh:

Substances:

Year:  2022        PMID: 36259133      PMCID: PMC9583214          DOI: 10.1177/03000605221129154

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.573


  20 in total

1.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Ann Intern Med       Date:  2007-10-16       Impact factor: 25.391

2.  High prevalence of colonisation with carbapenem-resistant Enterobacteriaceae among patients admitted to Vietnamese hospitals: Risk factors and burden of disease.

Authors:  Dien M Tran; Mattias Larsson; Linus Olson; Ngoc T B Hoang; Ngai K Le; Dung T K Khu; Hung D Nguyen; Tam V Vu; Tinh H Trinh; Thinh Q Le; Phuong T T Phan; Binh G Nguyen; Nhung H Pham; Bang H Mai; Tuan V Nguyen; Phuong T K Nguyen; Nhan D Le; Tuan M Huynh; Le T Anh Thu; Tran C Thanh; Björn Berglund; Lennart E Nilsson; Elin Bornefall; Le H Song; Håkan Hanberger
Journal:  J Infect       Date:  2019-05-21       Impact factor: 6.072

Review 3.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

4.  Carbapenemase-producing Enterobacteriaceae: Risk factors for infection and impact of resistance on outcomes.

Authors:  Shanthi Mariappan; Uma Sekar; Arunagiri Kamalanathan
Journal:  Int J Appl Basic Med Res       Date:  2017 Jan-Mar

5.  Hospital-acquired colonization and infections in a Vietnamese intensive care unit.

Authors:  Duong Bich Thuy; James Campbell; Le Thanh Hoang Nhat; Nguyen Van Minh Hoang; Nguyen Van Hao; Stephen Baker; Ronald B Geskus; Guy E Thwaites; Nguyen Van Vinh Chau; C Louise Thwaites
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

6.  Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae. A 5 year (2011-2016) case-control study.

Authors:  Luigi Segagni Lusignani; Elisabeth Presterl; Beata Zatorska; Miriam Van den Nest; Magda Diab-Elschahawi
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-17       Impact factor: 4.887

7.  Carbapenemase-producing Enterobacterales infections in COVID-19 patients.

Authors:  Vicente Pintado; Patricia Ruiz-Garbajosa; Rosa Escudero-Sanchez; Francesca Gioia; Sabina Herrera; Pilar Vizcarra; Jesús Fortún; Javier Cobo; Pilar Martín-Dávila; María Isabel Morosini; Rafael Cantón; Santiago Moreno
Journal:  Infect Dis (Lond)       Date:  2021-08-12

8.  Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies.

Authors:  Atul Sharma; Swapnil Tiwari; Manas Kanti Deb; Jean Louis Marty
Journal:  Int J Antimicrob Agents       Date:  2020-06-10       Impact factor: 15.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.